Antitumor action of α1-adrenoceptor blockers on human bladder, prostate and renal cancer cells

Pharmacology

Volumn 90, Issue 5-6, 2012, Pages 242-246

  Gotoh, Akinobu ^a   Nagaya, Hisao ^a   Kanno, Takeshi ^b   Nishizaki, Tomoyuki ^b  

^a Institute for Advanced Medical Sciences   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

1 Adrenoceptor blocker; Apoptosis; Bladder cancer; Prostate cancer; Renal cancer

Indexed keywords

NAFTOPIDIL; PRAZOSIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CELL STRAIN LNCAP; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; KIDNEY CANCER; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; KIDNEY NEOPLASMS; MALE; NAPHTHALENES; PIPERAZINES; PRAZOSIN; PROSTATIC NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 84866488801     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000342797     Document Type: Article

References (31)

1. Zhong H, Minneman KP: α1-Adrenoceptor subtypes. Eur J Pharmacol 1 999;375:261- 276.
2. Brede M, Philipp M, Knaus A, Muthig V, Hein L: α2-Adrenergic receptor subtypes - novel functions uncovered in gene-targeted mouse models. Biol Cell 2004;96:343-348. (Pubitemid 38807899)
3. Kaumann AJ, Molenaar P: Modulation of human cardiac function through 4 β-adrenoceptor populations. Naunyn Schmiedebergs Arch Pharmacol 1997;355:667-681. (Pubitemid 27395692)
4. Desiniotis A, Kyprianou N: Advances in the design and synthesis of prazosin derivatives over the last ten years. Expert Opin Ther Targets 2011;15:1405-1418.
5. Kyprianou N, Vaughan TB, Michel MC: Apoptosis induction by doxazosin and other quinazoline α1-adrenoceptor antagonists: a new mechanism for cancer treatment? Naunyn Schmiedebergs Arch Pharmacol 2009; 380:473-477.
6. Kanda H, Ishii K, Ogura Y, Imamura T, Kanai M, Arima K, Sugimura Y: Naftopidil, a selective α-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest. Int J Cancer 2008;122: 444-451. (Pubitemid 350234734)
7. Hori Y, Ishii K, Kanda H, Iwamoto Y, Nishikawa K, Soga N, Kise H, Arima K, Sugimura Y: Naftopidil, a selective α1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma. Cancer Prev Res (Phila) 2011;4:87-96.
8. Kanda H, Ishii K, Ogura Y, Imamura T, Kanai M, Arima K, Sugimura Y: Spontaneous regression of an asymptomatic meningioma associated with discontinuation of progesterone agonist administration. Neurol Med Chir (Tokyo) 2008;48:227-230.
9. Otsuki T, Kanno T, Fujita Y, Tabata C, Fukuoka K, Nakano T, Gotoh A, Nishizaki T: A3 adenosine receptor-mediated p53-dependent apoptosis in Lu-65 human lung cancer cells. Cell Physiol Biochem 2012;30:210-220.
10. Liou SF, Lin HH, Liang JC, Chen IJ, Yeh JL: Inhibition of human prostate cancer cells proliferation by a selective α1-adrenoceptor antagonist labedipinedilol-A involves cell cycle arrest and apoptosis. Toxicology 2009; 256:13-24.
11. Lin SC, Chueh SC, Hsiao CJ, Li TK, Chen TH, Liao CH, Lyu PC, Guh JH: Prazosin displays anticancer activity against human prostate cancers: targeting DNA and cell cycle. Neoplasia 2007;9:830-839.
12. Harris AM, Warner BW, Wilson JM, Becker A, Rowland RG, Conner W, Lane M, Kimbler K, Durbin EB, Baron AT, Kyprianou N: Effect of α1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study. J Urol 2007;178:2176-2180. (Pubitemid 47538576)
13. Alberti C: Apoptosis induction by quinazoline- derived α1-blockers in prostate cancer cells: biomolecular implications and clinical relevance. Eur Rev Med Pharmacol Sci 2007; 11:59-64. (Pubitemid 46487898)
14. Garrison JB, Kyprianou N: Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. Cancer Res 2006;66:464-472. (Pubitemid 43166055)
15. Walden PD, Globina Y, Nieder A: Induction of anoikis by doxazosin in prostate cancer cells is associated with activation of caspase- 3 and a reduction of focal adhesion kinase. Urol Res 2004;32:261-265. (Pubitemid 39222602)
16. Partin JV, Anglin IE, Kyprianou N: Quinazoline- based α1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-β signalling and IκBα induction. Br J Cancer 2003;88:1615-1621. (Pubitemid 36713791)
17. Siddiqui EJ, Shabbir M, Thompson CS, Mumtaz FH, Mikhailidis DP: Growth inhibitory effect of doxazosin on prostate and bladder cancer cells. Is the serotonin receptor pathway involved? Anticancer Res 2005; 25:4281-4286. (Pubitemid 41665217)
18. Kyprianou N: Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. J Urol 2003;169: 1520-1525. (Pubitemid 36323836)
19. Keledjian K, Kyprianou N: Anoikis induction by quinazoline based α1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2. J Urol 2003;169:1150-1156. (Pubitemid 36188191)
20. Anglin IE, Glassman DT, Kyprianou N: Induction of prostate apoptosis by α1- adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis 2002;5:88-95. (Pubitemid 34777889)
21. Cuellar DC, Rhee J, Kyprianou N: α1-Adrenoceptor antagonists radiosensitize prostate cancer cells via apoptosis induction. Anticancer Res 2002;22:1673-1679. (Pubitemid 34839180)
22. Kyprianou N, Jacobs SC: Induction of apoptosis in the prostate by α1-adrenoceptor antagonists: a novel effect of 'old' drugs. Curr Urol Rep 2000;1:89-96.
23. Benning CM, Kyprianou N: Quinazolinederived α1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an α1- adrenoceptor-independent action. Cancer Res 2002;62:597-602. (Pubitemid 34106437)
24. Kyprianou N, Benning CM: Suppression of human prostate cancer cell growth by α1- adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res 2000;60:4550-4555. (Pubitemid 32103639)
25. Tahmatzopoulos A, Sheng S, Kyprianou N: Maspin sensitizes prostate cancer cells to doxazosin-induced apoptosis. Oncogene 2005;24:5375-5383. (Pubitemid 43080107)
26. Liao CH, Guh JH, Chueh SC, Yu HJ: Antiangiogenic effects and mechanism of prazosin. Prostate 2011;71:976-984.
27. Keledjian K, Borkowski A, Kim G, Isaacs JT, Jacobs SC, Kyprianou N: Reduction of human prostate tumor vascularity by the α1- adrenoceptor antagonist terazosin. Prostate 2001;48:71-78. (Pubitemid 32613870)
28. Keledjian K, Garrison JB, Kyprianou N: Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion. J Cell Biochem 2005;94:374-388. (Pubitemid 41420315)
29. Tahmatzopoulos A, Lagrange CA, Zeng L, Mitchell BL, Conner WT, Kyprianou N: Effect of terazosin on tissue vascularity and apoptosis in transitional cell carcinoma of bladder. Urology 2005;65:1019-1023. (Pubitemid 40693015)
30. Fuchs R, Schraml E, Leitinger G, Stelzer I, Allard N, Haas HS, Schauenstein K, Sadjak A: α1-Adrenergic drugs modulate differentiation and cell death of human erythroleukemia cells through non adrenergic mechanism. Exp Cell Res 2011;317:2239-2251.
31. Takei R, Ikegaki I, Shibata K, Tsujimoto G, Asano T: Naftopidil, a novel α1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human α1-adrenoceptors. Jpn J Pharmacol 1999;79:447-454. (Pubitemid 29213362)